194 related articles for article (PubMed ID: 26311223)
41. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
[TBL] [Abstract][Full Text] [Related]
42. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer.
Leng Z; Xia Q; Chen J; Li Y; Xu J; Zhao E; Zheng H; Ai W; Dong J
Cell Physiol Biochem; 2018; 46(2):860-872. PubMed ID: 29627827
[TBL] [Abstract][Full Text] [Related]
43. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
[TBL] [Abstract][Full Text] [Related]
44. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.
Shiraishi A; Tachi K; Essid N; Tsuboi I; Nagano M; Kato T; Yamashita T; Bando H; Hara H; Ohneda O
Cancer Sci; 2017 Mar; 108(3):362-372. PubMed ID: 28012234
[TBL] [Abstract][Full Text] [Related]
45. Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater.
Piscuoglio S; Lehmann FS; Zlobec I; Tornillo L; Dietmaier W; Hartmann A; Wünsch PH; Sessa F; Rümmele P; Baumhoer D; Terracciano LM
J Clin Pathol; 2012 Feb; 65(2):140-5. PubMed ID: 22130902
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
47. By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis.
Gao J; Liu X; Yang F; Liu T; Yan Q; Yang X
Oncotarget; 2015 Sep; 6(29):27187-98. PubMed ID: 26356670
[TBL] [Abstract][Full Text] [Related]
48. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Vellon L; Menendez JA
Cell Cycle; 2011 Nov; 10(22):3871-85. PubMed ID: 22127234
[TBL] [Abstract][Full Text] [Related]
49. Molecular definition of breast tumor heterogeneity.
Shipitsin M; Campbell LL; Argani P; Weremowicz S; Bloushtain-Qimron N; Yao J; Nikolskaya T; Serebryiskaya T; Beroukhim R; Hu M; Halushka MK; Sukumar S; Parker LM; Anderson KS; Harris LN; Garber JE; Richardson AL; Schnitt SJ; Nikolsky Y; Gelman RS; Polyak K
Cancer Cell; 2007 Mar; 11(3):259-73. PubMed ID: 17349583
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
51. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.
Brooks DL; Schwab LP; Krutilina R; Parke DN; Sethuraman A; Hoogewijs D; Schörg A; Gotwald L; Fan M; Wenger RH; Seagroves TN
Mol Cancer; 2016 Mar; 15():26. PubMed ID: 27001172
[TBL] [Abstract][Full Text] [Related]
52. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
Terris B; Cavard C; Perret C
J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
[TBL] [Abstract][Full Text] [Related]
53. Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells.
Ke J; Zhao Z; Hong SH; Bai S; He Z; Malik F; Xu J; Zhou L; Chen W; Martin-Trevino R; Wu X; Lan P; Yi Y; Ginestier C; Ibarra I; Shang L; McDermott S; Luther T; Clouthier SG; Wicha MS; Liu S
Oncotarget; 2015 Feb; 6(6):3709-21. PubMed ID: 25686829
[TBL] [Abstract][Full Text] [Related]
54. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.
Gilboa-Geffen A; Hamar P; Le MT; Wheeler LA; Trifonova R; Petrocca F; Wittrup A; Lieberman J
Mol Cancer Ther; 2015 Oct; 14(10):2279-91. PubMed ID: 26264278
[TBL] [Abstract][Full Text] [Related]
55. Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.
Sankpal NV; Mayfield JD; Willman MW; Fleming TP; Gillanders WE
Breast Cancer Res; 2011; 13(6):R124. PubMed ID: 22132731
[TBL] [Abstract][Full Text] [Related]
56. Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.
Ionkina AA; Balderrama-Gutierrez G; Ibanez KJ; Phan SHD; Cortez AN; Mortazavi A; Prescher JA
Breast Cancer Res; 2021 Sep; 23(1):93. PubMed ID: 34579762
[TBL] [Abstract][Full Text] [Related]
57. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
[TBL] [Abstract][Full Text] [Related]
58. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
59. Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity.
Huber S; Wege AK; Bernhardt G; Buschauer A; Brockhoff G
Cytometry A; 2015 Aug; 87(8):707-16. PubMed ID: 25892097
[TBL] [Abstract][Full Text] [Related]
60. Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites.
Wintzell M; Hjerpe E; Åvall Lundqvist E; Shoshan M
BMC Cancer; 2012 Aug; 12():359. PubMed ID: 22901285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
